The global cholera vaccines market size is expected to reach USD 117.1 million by 2025

LONDON, Sept. 25, 2018 /PRNewswire/ -- Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025



Download the full report: https://www.reportbuyer.com/product/5568375



The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.2% during the forecast period. Increase in number of initiatives and rising awareness about cholera are major factors contributing toward market growth.

Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure.In February 2013, the Government of Haiti launched a 10-year National Cholera Elimination Plan.

The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.

Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa.Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks.

The Cholera Platform is working with the Global Task Force for Cholera Control (GTFCC) WASH working group. This association aims to develop a method for conducting case studies to control and prevent the disease.

Further key findings from the report suggest:
? The global market size was estimated at USD 63.1 million in 2017 and is expected to register a CAGR of 8.2% from 2017 to 2025
? By product, Dukoral vaccine dominated the market in 2017. The dominance can be attributed to the positive outcomes of this vaccine in preventing the disease since 2004. Dukoral is considered to be safe and stable
? The Vaxchora segment is expected to exhibit a lucrative CAGR over the forecast period owing to benefits associated with the vaccine, such as single dose immunization and reduced adverse effects
? Asia Pacific held the largest share in 2017 due to factors such as increasing incidence and growing initiatives for raising awareness about the disease and vaccination
? North America is anticipated to witness lucrative growth over the next decade due to a recent product launch and increasing number of travelers
? Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc.

Download the full report: https://www.reportbuyer.com/product/5568375

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer